Kite Pharma A Top Pick Ahead Of Axi-Cel Launch
June 27, 2017 at 08:27 AM EDT
Kite Pharma Inc (NASDAQ: KITE) is preparing to launch Axi-Cel, a chimeric antigen receptor T-cell therapy for non-Hodgkin’s ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.